Mechanisms of action of botulinum neurotoxins, β 3- adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011

Neurourology and Urodynamics

Volumn 31, Issue 3, 2012, Pages 300-308

  Kanai, Anthony ^a   Zabbarova, Irina ^a   Oefelein, Michael ^b   Radziszewski, Piotr ^c   Ikeda, Youko ^a   Andersson, Karl Erik ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

afferent nerve recording; intrinsic activity; neuropeptide release; optical mapping

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM; NEUROPEPTIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLADDER CONTRACTION; CELL TYPE; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR MUSCLE; DRUG ACTIVITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INCONTINENCE; MOUSE; NEUROGENIC BLADDER; NONHUMAN; OVERACTIVE BLADDER; REVIEW; SENSORY NERVE CELL;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; BOTULINUM TOXINS, TYPE A; CALCIUM SIGNALING; DECEREBRATE STATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; PHOSPHODIESTERASE 5 INHIBITORS; SENSORY RECEPTOR CELLS; SPINAL CORD INJURIES; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 84859102437     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21246     Document Type: Review

References (56)

1. Foran PG, Mohammed N, Lisk GO, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003; 278: 1363-71.
2. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-6.
3. Mahrhold S, Rummel A, Bigalke H, et al. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 2006; 580: 2011-4.
4. Carpenter FG,. Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rats. J Physiol 1967; 188: 1-11.
5. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-22.
6. Schurch B, Schmid DM, Stohrer M,. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665.
7. Smith CP,. Botulinum toxin in the treatment of OAB, BPH, and IC. Toxicon 2009; 54: 639-46.
8. Khera M, Somogyi GT, Salas NA, et al. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 2005; 66: 208-12.
9. Khera M, Somogyi GT, Kiss S, et al. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45: 987-93.
10. Kuo HC, Liao CH, Chung SD,. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome. Eur Urol 2010; 58: 919-26.
11. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European Consensus Report. Eur Urol 2009; 55: 100-19.
12. Kanai A, Zabbarova I, Ikeda Y, et al. Sophisticated models and methods for studying neurogenic bladder dysfunction. Neurourol Urodyn 2011; 30: 658-67.
13. Apostolidis A, Dasgupta P, Fowler CJ,. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-50.
14. Lucioni A, Bales GT, Lotan TL, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008; 101: 366-70.
15. Rapp DE, Turk KW, Bales GT, et al. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006; 175: 1138-42.
16. Morrison J,. The activation of bladder wall afferent nerves. Exp Physiol 1999; 84: 131-6.
17. + currents in capsaicin responsive DRG neurons. Exp Neurol 2009; 219: 562-73.
18. Ochodnicky P, Cruz CD, Yoshimura N, et al. Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 2011; 30: 1227-41.
19. Coelho A, Dinis P, Pinto R, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2010; 57: 884-90.
20. Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 473-81.
21. Limberg BJ, Andersson KE, Aura Kullmann F, et al. beta-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res 2010; 342: 295-306.
22. Fujimura T, Tamura K, Tsutsumi T, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol 1999; 161: 680-5.
23. Ursino MG, Vasina V, Raschi E, et al. The beta3-adrenoceptor as a therapeutic target: Current perspectives. Pharmacol Res 2009; 59: 221-34.
24. 3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn 2011; 30: 684-91.
25. 3-Adrenoceptors in urinary bladder. Neurourol Urodyn 2007; 26: 752-6.
26. 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 2010; 29: 771-6.
27. Apodaca G,. Stretch-regulated exocytosis of discoidal vesicles in urinary bladder epithelium. Urology 2001; 57: 103-4.
28. Birder LA, Apodaca G, De Groat WC, et al. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 1998; 275: F226-9.
29. Tyagi P, Tyagi V, Chancellor M,. Mirabegron: A safety review. Expert Opin Drug Saf 2011; 10: 287-94.
30. Giannitsas K, Mitropoulos D, Konstantinopoulos A, et al. Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. Expert Opin Pharmacother 2008; 9: 1687-93.
31. Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: A randomized, placebo controlled 12-week clinical trial. J Urol 2010; 183: 1092-7.
32. Gomelsky A, Dmochowski RR,. Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. Curr Urol Rep 2010; 11: 254-60.
33. Kraus SR, Dmochowski R, Albo ME, et al. Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. Neurourol Urodyn 2010; 29: 741-7.
34. Fry C, Kanai A, Roosen A, et al. Cell biology. In:, Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence, 4th edition. Paris: Health Publications, Ltd; 2009. 113-66.
35. Caremel R, Oger-Roussel S, Behr-Roussel D, et al. Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol 2010; 58: 616-25.
36. Behr-Roussel D, Oger S, Caisey S, et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol 2011; 59: 272-9.
37. 2+ channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol 2001; 86: 304-11.
38. Sculptoreanu A, de Groat WC,. Neurokinins enhance excitability in capsaicin-responsive DRG neurons. Exp Neurol 2007; 205: 92-100.
39. Lagou M, De Vente J, Kirkwood TB, et al. Location of interstitial cells and neurotransmitters in the mouse bladder. BJU Int 2006; 97: 1332-7.
40. Lagou M, Drake MJ, Markerink VANIM, et al. Interstitial cells and phasic activity in the isolated mouse bladder. BJU Int 2006; 98: 643-50.
41. Gillespie JI, Markerink-van Ittersum M, de Vente J,. cGMP-generating cells in the bladder wall: Identification of distinct networks of interstitial cells. BJU Int 2004; 94: 1114-24.
42. Gillespie JI, Markerink-van Ittersum M, de Vente J,. Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res 2005; 321: 341-51.
43. Gillespie JI, Markerink-van Ittersum M, De Vente J,. Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: Evidence for distinct populations of sub-urothelial interstitial cells. Cell Tissue Res 2006; 325: 325-32.
44. Gillespie JI, Markerink-van Ittersum M, De Vente J,. Interstitial cells and cholinergic signalling in the outer muscle layers of the guinea-pig bladder. BJU Int 2006; 97: 379-85.
45. Sui GP, Rothery S, Dupont E, et al. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int 2002; 90: 118-29.
46. Ikeda Y, Fry C, Hayashi F, et al. Role of gap junctions in spontaneous activity of the rat bladder. Am J Physiol Renal Physiol 2007; 293: F1018-25.
47. Ikeda Y, Kanai A,. Urotheliogenic modulation of intrinsic activity in spinal cord-transected rat bladders: Role of mucosal muscarinic receptors. Am J Physiol Renal Physiol 2008; 295: F454-61.
48. Sui GP, Wu C, Roosen A, et al. Modulation of bladder myofibroblast activity: Implications for bladder function. Am J Physiol Renal Physiol 2008; 295: F688-97.
49. 2+ signalling in urethral interstitial cells of Cajal. J Physiol 2006; 576: 715-20.
50. Yu Y, de Groat WC,. Sensitization of pelvic afferent nerves in the in vitro rat urinary bladder-pelvic nerve preparation by purinergic agonists and cyclophosphamide pretreatment. Am J Physiol Renal Physiol 2008; 294: F1146-56.
51. McCarthy CJ, Zabbarova IV, Brumovsky PR, et al. Spontaneous contractions evoke afferent nerve firing in mouse bladders with detrusor overactivity. J Urol 2009; 181: 1459-66.
52. Birder LA, Nealen ML, Kiss S, et al. Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci 2002; 22: 8063-70.
53. Romih R, Korosec P, Jezernik K, et al. Inverse expression of uroplakins and inducible nitric oxide synthase in the urothelium of patients with bladder outlet obstruction. BJU Int 2003; 91: 507-12.
54. Birder LA,. Role of the urothelium in urinary bladder dysfunction following spinal cord injury. Prog Brain Res 2006; 152: 135-46.
55. Smith CP, Vemulakonda VM, Kiss S, et al. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: Effect of botulinum toxin A. Neurochem Int 2005; 47: 291-7.
56. Andersson KE, Soler R, Fullhase C,. Rodent models for urodynamic investigation. Neurourol Urodyn 2011; 30: 636-46.